Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 253-261 , September 2009

Identifying factors that affect patients' willingness to pay for inhaled insulin

  • Sharrel L. Pinto, B.S.Pharm., Ph.D.

      Affiliations

    • Pharmaceutical Care and Outcomes Research Laboratory, Division of Pharmacy Health Care Administration, College of Pharmacy, The University of Toledo, Toledo, OH, USA
    • Corresponding Author InformationCorresponding author. Tel.: +419 530 1906; fax: +419 530 1950.
    • ,
  • Monica Holiday-Goodman, R.Ph., Ph.D.

      Affiliations

    • Division of Pharmacy Health Care Administration, College of Pharmacy, The University of Toledo, Toledo, OH, USA
    • ,
  • Curtis D. Black, Ph.D.

      Affiliations

    • Department of Pharmacy Practice, College of Pharmacy, The University of Toledo, Toledo, OH, USA
    • ,
  • David Lesch, B.S.P.S.

      Affiliations

    • Department of Pharmacy Practice, College of Pharmacy, The University of Toledo, Toledo, OH, USA

References 

  1. National Diabetes Fact Sheet . Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf2007;Accessed 07.10.08
  2. Behavioral Risk Factor Surveillance System, Prevalence Data . Available at: http://apps.nccd.cdc.gov/brfss/display.asp%3Fcat=DB&yr=2006&qkey=1363&state=USAccessed 03.03.08
  3. American Diabetes Association . Indirect costs of diabetes. Available at: http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jspAccessed 03.03.08
  4. National Diabetes Information Clearinghouse . National diabetes statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#1Accessed 03.03.08
  5. Center for Disease Control . Basics about diabetes. Available at: http://cdc.gov/diabetes/faq/basics.htmAccessed 03.03.08
  6. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997;20:292–298
  7. Cappelleri J, Cefalu W, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;4:552–564
  8. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235–247
  9. U.S. Food and Drug Administration . FDA approves first ever inhaled insulin combination product for treatment of diabetes. Available at: http://www.fda.gov/bbs/topics/news/2006/NEW01304.htmlAccessed 03.03.08
  10. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin Lispro and regular human insulin. Diabetes Care. 2005;28:1077–1082
  11. Barnett AH. Exubera inhaled insulin: a review. Int J Clin Pract. 2004;58(4):394–401
  12. Patton J, Bukar J, Eldon M. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43(12):781–801
  13. Wall JK. Lilly still breathing in inhaler pursuit: Pfizer's lackluster Exubera insulin launch could open door. IBJ Corp. 2007;
  14. Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics. 2004;22(6):375–387
  15. Lenert LA. Use of willingness to pay to study values for pharmacotherapies for migraine headache. Med Care. 2003;41(2):299–308
  16. O'Brien BJ, Novosel S, Torrance G, Streiner D. Assessing the economic value of a new antidepressant. A willingness to pay approach. Pharmacoeconomics. 1995;8(1):34–45
  17. Sadri H, MacKeigan LD, Leiter LA, et al. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics. 2005;23(12):1215–1227
  18. Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes mellitus: a randomized controlled trial. Diabetes Care. 2001;24:1556–1559
  19. Rosenstock J, Cappelleri JC, Bolinder , et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27:1318–1323
  20. Gorsuch R. Exploratory factor analysis: its role in item analysis. J Pers Assess. 1997;68(3):532–560
  21. Guadagnoli E, Velicer W. Relation of sample size to the stability of component patterns. Psychol Bull. 1988;103:265–275
  22. Dranitsaris G, Longo C, Grossman L. The economic value of a new insulin preparation, Humalog mix 25. Pharmacoeconomics. 2000;18(3):257–287
  23. Barron A, Lee T, Taylor J, et al. Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. Arthritis Rheum. 2004;51(6):899–908
  24. Stevens J. Applied Multivariate Statistics for the Social Sciences. 4th ed.. Mahwah: Lawrence Erlbaum Associates Inc; 2002;
  25. Algina J, Olejnik S. Determining sample size for accurate estimation of the squared multiple correlation coefficient. Multivariate Behav Res. 2000;35(1):119–137
  26. Cappelleri JC, Kourides IA, Gerber RA, et al. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for Type 1 diabetes. Diabetes Care. 2000;23(12):1799–1803
  27. Frew E, Wolstenholme JL, Whynes DK. Willingness-to-pay for colorectal cancer screening. Eur J Cancer. 2001;37:1746–1751
  28. Cross MJ, March LM, Lapsley HM, et al. Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis. Rheumatology. 2000;39:1242–1248
  29. Smith ASA, Cunningham SJ. Which factors influence willingness-to-pay for orthognathic treatment?. Eur J Orthod. 2004;26(5):499–506
  30. Catell RB. The scree test for number of factors. Multivariate Behav Res. 1966;1:245–276
  31. Zethraeus N. Willingness to pay for hormone replacement therapy. Health Econ. 1998;7:31–38
  32. Kartman B. Willingness-to-pay for reductions in angina pectoris attacks. Med Decis Making. 1996;16:248–253
  33. Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008;
  34. Jonsson PM, Sterky G, Gafvels C, Ostman J. Gender equity in health care: the case of Swedish diabetes care. Health Care Women Int. 2000;5:413–431
  35. Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008;26(3):235–249
  36. Pinto-Prades JL, Farreras V, de Bobadilla JF. Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. Eur J Health Econ. 2008 Feb;9(1):69–78
  37. Mahadevia P, Shah S, Mannix S, et al. Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis. J Manag Care Pharm. 2006 Mar;12(2):143–151
  38. Wall St J. Available at: http://online.wsj.com/article/SB119269071993163273.html. Accessed 23.05.08.
  39. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18:S42–S49

PII: S1551-7411(08)00095-8

doi: 10.1016/j.sapharm.2008.10.001

Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 253-261 , September 2009

Article Tools